BioCardia with ticker code (BCDA) now have 4 analysts covering the stock with the consensus suggesting a rating of ‘Buy’. The range between the high target price and low target price is between 19 and 7 with the average target price sitting at 12.88. Given that the stocks previous close was at 3.79 this would indicate that there is a potential upside of 239.8%. The 50 day MA is 3.41 while the 200 day moving average is 2.6. The market capitalisation for the company is $53m. Visit the company website at: http://www.biocardia.com
BioCardia, a clinical-stage regenerative medicine company, develops therapeutics for cardiovascular diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia. The company is also developing CardiALLO Cell Therapy System, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system, a percutaneous catheter delivery system for cardiovascular regenerative medicine; and Morph deflectable guides and sheaths. The company is based in San Carlos, California.